Stryker commits $400 million to CMR Surgical with option to acquire it

On October 12, 2026, Stryker and CMR Surgical announced an alliance under which Stryker agreed to provide approximately $400 million (£300 million) in preferred equity financing. Stryker receives an exclusive option to buy all of CMR Surgical and will act as the exclusive U.S. sales agent for CMR’s Versius robotic-surgery portfolio. CMR will continue developing and commercializing the portfolio outside the United States, while the transaction remains subject to regulatory approvals and customary closing conditions.

The agreement gives Stryker immediate commercial access to Versius in the United States and a potential path to full ownership of CMR Surgical. Stryker describes the arrangement as an entry into soft-tissue robotics that combines CMR’s technology with Stryker’s commercial reach.

  • 1Stryker agreed to provide CMR Surgical with approximately $400 million (£300 million) in preferred equity financing.
  • 2The financing gives Stryker an exclusive option to acquire 100% of CMR Surgical’s outstanding equity.
  • 3Stryker will be the exclusive U.S. sales agent for the Versius portfolio, while CMR retains responsibility for development and commercialization outside the United States.
  • 4The transaction requires regulatory approvals and customary closing conditions.
  • The investment’s closing status is not fully clear because some materials describe it as completed, while the primary announcement says it remains subject to closing conditions and regulatory approvals.

Sources